These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 30824613)

  • 1. Nanobody Targeting of Epidermal Growth Factor Receptor (EGFR) Ectodomain Variants Overcomes Resistance to Therapeutic EGFR Antibodies.
    Tintelnot J; Baum N; Schultheiß C; Braig F; Trentmann M; Finter J; Fumey W; Bannas P; Fehse B; Riecken K; Schuetze K; Bokemeyer C; Rösner T; Valerius T; Peipp M; Koch-Nolte F; Binder M
    Mol Cancer Ther; 2019 Apr; 18(4):823-833. PubMed ID: 30824613
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Functional dissection of the epidermal growth factor receptor epitopes targeted by panitumumab and cetuximab.
    Voigt M; Braig F; Göthel M; Schulte A; Lamszus K; Bokemeyer C; Binder M
    Neoplasia; 2012 Nov; 14(11):1023-31. PubMed ID: 23226096
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epidermal Growth Factor Receptor Targeting in Colorectal Carcinoma: Antibodies and Patient-Derived Organoids as a Smart Model to Study Therapy Resistance.
    Tardito S; Matis S; Zocchi MR; Benelli R; Poggi A
    Int J Mol Sci; 2024 Jun; 25(13):. PubMed ID: 39000238
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MM-151 overcomes acquired resistance to cetuximab and panitumumab in colorectal cancers harboring EGFR extracellular domain mutations.
    Arena S; Siravegna G; Mussolin B; Kearns JD; Wolf BB; Misale S; Lazzari L; Bertotti A; Trusolino L; Adjei AA; Montagut C; Di Nicolantonio F; Nering R; Bardelli A
    Sci Transl Med; 2016 Feb; 8(324):324ra14. PubMed ID: 26843189
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel EGFR ectodomain mutations associated with ligand-independent activation and cetuximab resistance in head and neck cancer.
    Nair S; Trummell HQ; Rajbhandari R; Thudi NK; Nozell SE; Warram JM; Willey CD; Yang ES; Placzek WJ; Bonner JA; Bredel M
    PLoS One; 2020; 15(2):e0229077. PubMed ID: 32069320
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Affinity enhancement of nanobody binding to EGFR: in silico site-directed mutagenesis and molecular dynamics simulation approaches.
    Farasat A; Rahbarizadeh F; Hosseinzadeh G; Sajjadi S; Kamali M; Keihan AH
    J Biomol Struct Dyn; 2017 Jun; 35(8):1710-1728. PubMed ID: 27691399
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effects of somatic mutations on EGFR interaction with anti-EGFR monoclonal antibodies: Implication for acquired resistance.
    Tabasinezhad M; Omidinia E; Talebkhan Y; Omrani MD; Mahboudi F; Ghaedi H; Wenzel W
    Proteins; 2020 Jan; 88(1):3-14. PubMed ID: 31228284
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular Basis for Necitumumab Inhibition of EGFR Variants Associated with Acquired Cetuximab Resistance.
    Bagchi A; Haidar JN; Eastman SW; Vieth M; Topper M; Iacolina MD; Walker JM; Forest A; Shen Y; Novosiadly RD; Ferguson KM
    Mol Cancer Ther; 2018 Feb; 17(2):521-531. PubMed ID: 29158469
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Colorectal adenocarcinoma-derived EGFR mutants are oncogenic and sensitive to EGFR-targeted monoclonal antibodies, cetuximab and panitumumab.
    Kim N; Cho D; Kim H; Kim S; Cha YJ; Greulich H; Bass A; Cho HS; Cho J
    Int J Cancer; 2020 Apr; 146(8):2194-2200. PubMed ID: 31290142
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multivalent Rhamnose-Modified EGFR-Targeting Nanobody Gains Enhanced Innate Fc Effector Immunity and Overcomes Cetuximab Resistance via Recruitment of Endogenous Antibodies.
    Li Y; Lin H; Hong H; Li D; Gong L; Zhao J; Wang Z; Wu Z
    Adv Sci (Weinh); 2024 Apr; 11(13):e2307613. PubMed ID: 38286668
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The First-in-class Anti-EGFR Antibody Mixture Sym004 Overcomes Cetuximab Resistance Mediated by EGFR Extracellular Domain Mutations in Colorectal Cancer.
    Sánchez-Martín FJ; Bellosillo B; Gelabert-Baldrich M; Dalmases A; Cañadas I; Vidal J; Martinez A; Argilés G; Siravegna G; Arena S; Koefoed K; Visa L; Arpí O; Horak ID; Iglesias M; Stroh C; Kragh M; Rovira A; Albanell J; Tabernero J; Bardelli A; Montagut C
    Clin Cancer Res; 2016 Jul; 22(13):3260-7. PubMed ID: 26888827
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of a mutation in the extracellular domain of the Epidermal Growth Factor Receptor conferring cetuximab resistance in colorectal cancer.
    Montagut C; Dalmases A; Bellosillo B; Crespo M; Pairet S; Iglesias M; Salido M; Gallen M; Marsters S; Tsai SP; Minoche A; Seshagiri S; Serrano S; Himmelbauer H; Bellmunt J; Rovira A; Settleman J; Bosch F; Albanell J
    Nat Med; 2012 Jan; 18(2):221-3. PubMed ID: 22270724
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune Effector Functions of Human IgG2 Antibodies against EGFR.
    Rösner T; Kahle S; Montenegro F; Matlung HL; Jansen JHM; Evers M; Beurskens F; Leusen JHW; van den Berg TK; Valerius T
    Mol Cancer Ther; 2019 Jan; 18(1):75-88. PubMed ID: 30282813
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modulating antibody-dependent cellular cytotoxicity of epidermal growth factor receptor-specific heavy-chain antibodies through hinge engineering.
    D'Eall C; Pon RA; Rossotti MA; Krahn N; Spearman M; Callaghan D; van Faassen H; Hussack G; Stetefeld J; Butler M; Durocher Y; Zhang J; Henry KA; Tanha J
    Immunol Cell Biol; 2019 Jul; 97(6):526-537. PubMed ID: 30680791
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nanobody-based CD38-specific heavy chain antibodies induce killing of multiple myeloma and other hematological malignancies.
    Schriewer L; Schütze K; Petry K; Hambach J; Fumey W; Koenigsdorf J; Baum N; Menzel S; Rissiek B; Riecken K; Fehse B; Röckendorf JL; Schmid J; Albrecht B; Pinnschmidt H; Ayuk F; Kröger N; Binder M; Schuch G; Hansen T; Haag F; Adam G; Koch-Nolte F; Bannas P
    Theranostics; 2020; 10(6):2645-2658. PubMed ID: 32194826
    [No Abstract]   [Full Text] [Related]  

  • 16. CCI-779 (Temsirolimus) exhibits increased anti-tumor activity in low EGFR expressing HNSCC cell lines and is effective in cells with acquired resistance to cisplatin or cetuximab.
    Niehr F; Weichert W; Stenzinger A; Budach V; Tinhofer I
    J Transl Med; 2015 Apr; 13():106. PubMed ID: 25890004
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II Study of Tivantinib and Cetuximab in Patients With KRAS Wild-type Metastatic Colorectal Cancer With Acquired Resistance to EGFR Inhibitors and Emergence of MET Overexpression: Lesson Learned for Future Trials With EGFR/MET Dual Inhibition.
    Rimassa L; Bozzarelli S; Pietrantonio F; Cordio S; Lonardi S; Toppo L; Zaniboni A; Bordonaro R; Di Bartolomeo M; Tomasello G; Dadduzio V; Tronconi MC; Piombo C; Giordano L; Gloghini A; Di Tommaso L; Santoro A
    Clin Colorectal Cancer; 2019 Jun; 18(2):125-132.e2. PubMed ID: 30846365
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis and Characterization of Cetuximab-Docetaxel and Panitumumab-Docetaxel Antibody-Drug Conjugates for EGFR-Overexpressing Cancer Therapy.
    Glatt DM; Beckford Vera DR; Prabhu SS; Mumper RJ; Luft JC; Benhabbour SR; Parrott MC
    Mol Pharm; 2018 Nov; 15(11):5089-5102. PubMed ID: 30226780
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting EGFR and RAS/RAF Signaling in the Treatment of Metastatic Colorectal Cancer: From Current Treatment Strategies to Future Perspectives.
    Mizukami T; Izawa N; Nakajima TE; Sunakawa Y
    Drugs; 2019 Apr; 79(6):633-645. PubMed ID: 30968289
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.